share_log

Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO

Moomoo 24/7 ·  Apr 3 02:45

Abstract Number: 2106

Title: Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM)

Session Title: Rapid Oral Abstract – Central Nervous System Tumors
Session Date: June 2, 2024
Session Time: 11:30 AM – 1:00 PM

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment